Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure ...

A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS ...

The Windsor Framework marks a significant change in the UK's post-Brexit regulatory space, particularly for the ...

As such, the 2nd Peptide Formulation & Delivery Innovation Summit (June 24 - 26, 2025 | Boston, MA) returns as the only ...

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...